Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

A New Prognostic Score Using Lymphocyte to Monocyte Ratio and Immunoglobulin Levels to Predict Progression in Multiple Myeloma Patients Undergoing Autologous Transplant

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Jonathan Lee, Nadim Mahmud, MBBS, PhD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 3442.

https://doi.org/10.1182/blood-2018-99-118965

Published: 2018

Journal Articles

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Sonia Christian, MD, Kelley E. Kozma, DO, Stephanie Barath, Ardaman Shergill, MD, Damiano Rondelli, MD, David Peace, MD, Santosh L. Saraf, MD, Annie Lee Oh, MD, Karen Sweiss, PharmD, Irum Khan, MBBS, Pritesh Patel, MD, Arkadiusz Dudek, MD PhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 5218.

https://doi.org/10.1182/blood-2018-99-111412

Published: 2018

Journal Articles

Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma

Gregory Sampang Calip, PharmD, MPH, PhD, Jifang Zhou, MD, Karen Sweiss, PharmD, Pritesh Patel, MD, Alemseged Ayele Asfaw, MSc, B Pharm, Todd Lee, PharmD, PhD, Brian C.-H. Chiu, PhD, Edith A. Nutescu, PharmD., MS, FCCP

Blood (2018) 132 (Supplement 1): 4693.

https://doi.org/10.1182/blood-2018-99-116867

Published: 2018

Journal Articles

Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Jeremy Johnson, PharmD, PhD, Hyunyoung Jeong, PharmD, PhD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 4621.

https://doi.org/10.1182/blood-2018-99-117623

Published: 2018

Journal Articles

A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Sonia Christian, MD, Pritesh Patel, MD, Vaibhav Agrawal, MD MBA, Shawn Griffin, PharmD, Kirk Cahill, MD, Irum Khan, MBBS, Karen Sweiss, PharmD, Ardaman Shergill, MD, Gregory Sampang Calip, PharmD,MPH,PhD, Wendy Stock, MD, Olatoyosi Odenike, MD, Heiko Konig, MDPhD, John G. Quigley

Blood (2018) 132 (Supplement 1): 1397.

https://doi.org/10.1182/blood-2018-99-111389

Published: 2018

Journal Articles

Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas

Inyoung Lee, MS, BPharm, Sruthi Adimadhyam, BPharm, MS, Edith A. Nutescu, PharmD., MS, FCCP, Karen Sweiss, PharmD, Pritesh Patel, MD, Gregory Sampang Calip, PharmD, MPH, PhD

Blood (2018) 132 (Supplement 1): 2280.

https://doi.org/10.1182/blood-2018-99-116938

Published: 2018

Journal Articles

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

Karen Sweiss, PharmD, Gregory Sampang Calip, PharmD, MPH, PhD, Scott Wirth, PharmD, Damiano Rondelli, MD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 3542.

https://doi.org/10.1182/blood-2018-99-117657

Published: 2018

Journal Articles

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Pritesh Patel, MD, Vitalyi Senyuk, PhD, Natalie S. Rodriguez, MS, Dolores Mahmud, PhD, Annie Lee Oh, MD, Nadim Mahmud, MBBS, PhD, Giovanni Barosi, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 3319.

https://doi.org/10.1182/blood-2018-99-119497

Published: 2018

Journal Articles

Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma

Gregory Sampang Calip, PharmD, MPH, PhD, Karen Sweiss, PharmD, Sruthi Adimadhyam, BPharm, MS, Alemseged Ayele Asfaw, MSc, B Pharm, Jifang Zhou, MD, Zhaoju Wu, MD PhD, Todd Lee, PharmD, PhD, Brian C.-H. Chiu, PhD, Pritesh Patel, MD

Blood (2018) 132 (Supplement 1): 1888.

https://doi.org/10.1182/blood-2018-99-116412

Published: 2018

Journal Articles

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

Santosh L. Saraf, MD, Krishna Ghimire, MD, Pritesh Patel, MD, Karen Sweiss, PharmD, John G. Quigley, Irum Khan, MBBS, David Peace, MD, Michel Gowhari, DO, Shivi Jain, MD, John P. Galvin, MDMS,MPH, Robert E. Molokie, MD, Victor R. Gordeuk, MD, Damiano Rondelli, MD

Blood (2018) 132 (Supplement 1): 313.

https://doi.org/10.1182/blood-2018-99-113666

Published: 2018

NARROW

A New Prognostic Score Using Lymphocyte to Monocyte Ratio and Immunoglobulin Levels to Predict Progression in Multiple Myeloma Patients Undergoing Autologous Transplant

A Safety Study of the Addition of Omacetaxine to the Standard-of-Care Induction Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients

Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma

Pre-Transplant Hemoglobin and Creatinine Clearance Correlate with Treatment Free Survival in Patients with Myeloma Receiving Mel200 and Autologous Stem Cell Transplantation

A Multi-Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) Vs High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Arterial and Venous Thromboembolic Safety of Bevacizumab in Patients with High Grade Gliomas

Collaborative Physician-Pharmacist Managed Multiple Myeloma Clinic Decreases Polypharmacy, Improves Guideline Adherence, and Prevents Treatment Delays

PARP Inhibitor Veliparib and Busulfan in a Xenograft Model of Myeloproliferative Neoplasm

Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma

Health Care Utilization in Transplanted Versus Non-Transplanted Sickle Cell Disease Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only